Agios Pharmaceuticals (AGIO)

• Market cap: $2.17B
• 1 day: 0.30%
• 5 days: 3.95%
• 1 month: 0.46%
• 3 months: 23.74%
• 6 months: 8.51%
• Year to date: 17.37%
• 1 year: -19.76%
• 5 years: -3.26%
• 10 years: -57.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Employees: 488

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

24% more call options, than puts

Call options by funds: $9.22M | Put options by funds: $7.42M

16% more capital invested

Capital invested by funds: $1.76B [Q1] → $2.05B (+$288M) [Q2]

15% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 75

1.61% more ownership

Funds ownership: 104.73% [Q1] → 106.34% (+1.61%) [Q2]

4% less funds holding

Funds holding: 218 [Q1] → 210 (-8) [Q2]

15% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 26

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $51 36% upside
• Avg. target: $58 55% upside
• High target: $65 74% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Scotiabank Greg Harrison	74% upside $65	Sector Outperform Maintained	28 Jul 2025
B of A Securities Greg Harrison	36% upside $51	Buy Maintained	22 Jul 2025